ABPI statement on BGMA legal action over Voluntary Scheme negotiation representation

The British Generic Manufacturers Association (BGMA) is seeking a judicial review of the Department of Health and Social Care’s (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI).

For over 60 years, and in accordance with the National Health Service Act 2006, the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines.

Richard Torbett, Chief Executive of the ABPI said: “We are disappointed that the BGMA has decided to take this action - but we recognise that it has been perpetuated by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates.

“The ABPI takes our responsibility to represent the entire branded medicine market extremely seriously, consistently engaging and involving the wider life sciences industry and trade associations as we approach the start of formal negotiations.

“Working with the whole industry we have developed and published a positive and pragmatic vision for a new voluntary scheme that supports value for the NHS, medicines access for patients, and economic growth.

“We now look forward to starting detailed discussions with the Government as soon as possible to ensure timely agreement of a new Voluntary Scheme.”

“As negotiations progress, the ABPI will update global Chief Executives on progress at key moments in June and September to support them in their 2024 financial planning and investment decisions.”